Purisys

a DEA-licensed (Schedule I-V) bulk manufacturer of ultra-high-purity CBD/THC isolates under FDA Drug Master File and GMP certification, recently acquired by Siegfried, a global pharmaceutical CDMO.

Country: United States

gmp us

Coverage

	CN	EU	US
specialty-fine-chem	✓	✓	✓

Regulatorsfdaemanmpa

Verifiable facts

Fact	Value	Source
Revenue	$6.6M estimated annual revenue medium confidence	marketscreener.com · process-worldwide.com · siegfried.ch
Funding	Acquired by Siegfried Holding AG for a valuation below 10 times EBITDA	marketscreener.com · siegfried.ch
Production site	1550 Olympic Drive, Athens, Georgia 30601, United States	mtec-sc.org · moreblossom.com
Certification	cGMP compliant and FDA-inspected facilities	mtec-sc.org · moreblossom.com · preqin.com
Regulatory approval	DEA-licensed for Schedule I-V controlled substances	federalregister.gov · moreblossom.com

Independent sources: federalregister.gov · marketscreener.com · moreblossom.com · mtec-sc.org · preqin.com · process-worldwide.com · siegfried.ch

Technologies

Name	Cluster	Risk
Biosynthetic cannabinoids (CBD & THC)	specialty-fine-chem	Medium	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.